emyria

ASX : EMD

RESPONDING TO AUSTRALIA'S MENTAL HEALTH CRISIS

Advanced therapies.
Compassionate care.



04 February 2025
Euroz Healthcare Forum

DISCLAIMER

This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown.

The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products' ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy.

THE GROWING GLOBAL MENTAL HEALTH CHALLENGE



Half of the global population
will experience mental illness. [1]

Mental health disorders could cost the world $16 trillion by 2030. [2]

SOURCES:
1. https://hms.harvard.edu/news/half-worlds-population-will-experience-mental-health-disorder
2. The Lancet Commission on global mental health and sustainable development; Published 10 October 2018

AUSTRALIAN MENTAL HEALTH | ANNUAL EXPENDITURE COMPARISON

Increasing amounts being spent on mental health...



SOURCES:
1. https://www.aihw.gov.au/reports/cancer/health-system-expenditure-cancer-other-neoplasms/summary
2. https://www.aihw.gov.au/mental-health/topic-areas/expenditure

AUSTRALIAN MENTAL HEALTH | NOW OUR #1, RISING, CHRONIC HEALTH PROBLEM

...yet, ***prevalence*** *of mental health is increasing*

Figure 2: Types of serious illness by age and sex, 2009 to 2021



Figure 2: Estimated proportion of Australians reporting serious illnesses, by sex and age group, 2009–2021.

https://www.aihw.gov.au/mental-health

AUSTRALIAN MENTAL HEALTH | WORKFORCE UNDER PRESSURE

1. The mental health crisis gripping Australia's private hospitals

Some health insurers say stand-alone mental health hospitals are unlikely to exist in 10 years' time given the challenges they face.

2. 'Declaration of war': NSW government's plan for mental health system slammed amid psychiatrist resignations

3. Australians' mental health drops to 4-year low

Businesses losing up to 69 workdays of productivity annually per employee due to poor mental health: report

4. Bethesda Clinic to close nine months after opening due to lack of psych doctors and funding issues

5. 70% of Australians with depressive disorders not getting adequate treatment



emyria

SOURCES:
1. Financial Review, 25 October 2024
2. Channel 9 News 23 January 2025
3. Human Resources Director, 23 November 2024
4. The West Australian, 05 February 2024
5. UQ News, 22 November 2024
6. Household, Income and Labour Dynamics Survey, 2021

AUSTRALIA'S UNIQUE OPPORTUNITY | AN ACCESS PATHWAY FOR TWO **NEW** TREATMENTS



Australia is the ONLY jurisdiction in the world to reschedule two promising treatments [1]

Home > News and Community > Media releases

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists

Published: 3 February 2023

Listen Print Share

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

MDMA



Psilocybin



PSYCHEDELICS TO TACKLE TREATMENT RESISTANT **PTSD** and **DEPRESSION**

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder

PTSD is a chronic, debilitating condition that can develop after experiencing, or repeatedly being exposed to, traumatic events

7%
of adults [1]
1.5m *Australians*
23m *Americans*



Psilocybin-Assisted Therapy for Treatment-Resistant Depression

TR-D is major depression that does not improve after trialling 2 or more medications

4.4%
of adults [3]
1.1m *Australians*
16m *Americans*

$2.3B
per year.
Treatment costs in Australia [4]

emyria

SOURCES:
1. https://www.phoenixaustralia.org/ptsd-awareness-day/
2. Obuobi-Donkor G, et al A Scoping Review on the Prevalence and Determinants of Post-Traumatic Stress Disorder among Military Personnel and Firefighters: Implications for Public Policy and Practice. Int J Environ Res Public Health. 2022 Jan 29;19(3):1565. doi: 10.3390/ijerph19031565.
3. https://www.sciencedirect.com/science/article/pii/S2772598724000230
4. https://research-management.mq.edu.au/ws/portalfiles/portal/112464237/112458032.pdf

PSYCHEDELIC-ASSISTED THERAPY | A NEW TREATMENT PARADIGM

Potent, psychoactive medications





Intensive and supportive psychotherapy



Specialists ***Therapists***

emyria

CASE STUDY | *KATE* | FROM WORKERS COMP TO BACK-TO-WORK



Kate's story: **First responder**

- **PTSD** due to cumulative workplace traumas
- Myriad of **therapies**: EMDR, in-vivo, ACT, CBT, mindfulness, somatic exercises, TMS, imagery rescripting, nightmare rescripting. Different psychotropic **medications**
- Stuck, terrified and tortured by her unrelenting symptoms and her psychological defenses.
- Despite all efforts and commitment, **treatment** and **therapy resistant**

Soon after MDMA-AT, Kate sought employment again after nearly 5 years.

emyria

SOURCES:
1. The **PCL-5** is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).

EMYRIA'S PTSD PROGRAM | 3 MONTHS POST-TREATMENT | *SYMPTOM IMPROVEMENT*

Average PCL-5 [1] Scores by Visit (up to 3 months follow-up)



SOURCES:
1. The **PCL-5** is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition).

EMYRIA'S PTSD PROGRAM | 3 MONTHS POST-TREATMENT | *Quality of Life IMPROVEMENT*

Average ReQoL [1] Scores by Visit (up to 3 months follow-up)



SOURCES:
1. The **ReQoL** is a patient-reported outcome measure covering domains such as wellbeing, functioning, and personal recovery, allowing patients to express how their mental health impacts their daily lives and overall quality of life.

WHY CAN'T EVERYONE DO THIS? THE SIGNIFICANT BARRIERS TO ENTRY!

✓

TGA Approved Authorised Prescribers

Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

✓

Secure, pharmaceutical-grade medication supply



WORLD-CLASS FACILITIES AND A SKILLED TEAM OF CLINICIANS

Emyria's team of over 20 trained clinicians comprise:

- *Specialist psychiatrists,*
- *psychologists,*
- *mental health*
- *nurses, counsellors,*
- *social workers and;*
- *occupational therapists*



Figure 1:
12 of Emyria's twenty trained therapists.

LIFETIME PREVALENCE OF SERIOUS MENTAL ILLNESS IN AUSTRALIA (million persons)





emyria

SOURCES:
1. Australian Bureau of Statistics, accessed 31 Jan 2025

ADDRESSABLE PATIENT POPULATION, TODAY





Avg treatment costs $20k-$30k / pt

Total addressable market ~ $36B

emyria

SOURCES:
1. Australian Bureau of Statistics, accessed 31 Jan 2025
2. For workings, please refer to Slide 24
3. 5. Treatment cost varies depending on average number of treatment cycles per patient, per condition. Emyria's programs average 3 treatment cycles for MDMA-AT and 2 treatment cycles for TR-Depression

GROWTH OPPORTUNITY TO TACKLE ADDITIONAL UNMET NEEDS





SOURCES:
1. Australian Bureau of Statistics, accessed 31 Jan 2025

EMYRIA'S GROWTH STRATEGY

Establish world-class, dedicated treatment centres, specialising in new psychiatric treatments [1]



Expansion to be supported by provider agreements with major private and government funders



Leverage Emyria's proprietary Real-World Data to create better care models & treatments



SOURCES:
1. See ASX release 10 April 2024
3. See ASX release 28 October 2024

*The **only ASX-listed entity** integrating direct care in psychedelic-assisted therapy*

MAJOR UNMET NEEDS - MENTAL HEALTH

Emyria is tackling multiple, large and urgent unmet needs.

A HARD-TO-COPY TREATMENT THAT WORKS

Emyria is already delivering encouraging clinical outcomes and has a proven delivery model.

AN INCREDIBLE TEAM

Expertise in mental health, national clinic expansion, Real-World Data and new care model development.

CLEAR GROWTH STRATEGY BACKED BY MAJOR HEALTH PAYERS

We're in advanced discussions with major payers to help facilitate expansion and better patient access nationally.

STRONG IP

Data captured through clinics creates intellectual property and supports long-term drug development programs.

CONTACT INFORMATION

Greg Hutchinson ghutchinson@emyria.com
Michael Winlo mwinlo@emyria.com
Investor / Media Inquiries investors@emyria.com

Visit Our Investor Hub



PSYCHEDELIC-ASSISTED THERAPY | INVESTMENT INTEREST IS RETURNING

Investor confidence in psychedelics is returning, driven by shifting political landscapes in the US that may signal broader acceptance and support for these treatments.

POLITICO [1]

The buzz about Trump and psychedelics

By **ERIN SCHUMAKER, DANIEL PAYNE, RUTH READER** and **CARMEN PAUN** | 11/11/2024 02:00 PM EST

Donald Trump's return to the White House could be a bright spot in an otherwise brutal year for the psychedelic medicine movement.

Most Attractive Investment Areas Q3'24 [2]



emyria

Sources:
1. https://www.politico.com/newsletters/future-pulse/2024/11/11/the-buzz-about-trump-and-psychedelics-00188669
2. Q3'24 Results: The Psychedelic Investor Survey - Psychedelic Alpha - https://psychedelicalpha.com/news/psychedelic-investor-survey-q3-2024

CORPORATE OVERVIEW

SUBSTANTIAL SHAREHOLDERS	
Shareholder	**%**
#1 Holder: Greg Hutchinson, Chairman	7.2% [1]
Top 50	65.9%

ASX: EMD TRADING INFORMATION	
Last Traded Share Price	**A$0.035**
12-Month low / high	A$0.026 / 0.076
Shares Outstanding	455,471,286
Market Capitalisation [2]	**A$15.6M**
Last Cash Position [3]	A$1,550,000 *(With additional $1,000,000 subject to shareholder approval [1])*

NOTES:
1. Subject to shareholder approval to be sought at an upcoming EGM, anticipated March 2025
2. As of close of market 03 Feb 2025
3. As reported in December Quarterly Report

emyria

EMYRIA LEADERSHIP | SIGNIFICANT CLINICAL SERVICES AND INNOVATION EXPERTISE



Greg Hutchinson
Executive Chairman

- **Health Service Leadership:** CEO Sonic HealthPlus and 5D Clinics; leads 40+ clinics



Dr Michael Winlo
Executive Director

- **Research & Data Expertise:** Ex-Palantir healthcare lead, merging Medical Doctor and Stanford MBA



Dr Karen Smith
Non-Executive Director

- **Biopharma Executive:** 100+ clinical trials and 20+ regulatory approvals; Former Chief Medical Officer and Global Head of R&D at Jazz Pharma



Dr Mohit Kaushal
Non-Executive Director

- **Health IT Strategist:** Key role in Oak Street Health's $10.6B acquisition by CVS Health; Served in Obama's Health IT task force; Adjunct Professor at Stanford



Prof Sir John Tooke
Non-Executive Director

- **Clinical Service & Health Payer Expertise:** Former President of the Academy of Medical Sciences, influential roles at BUPA and past advisor to Google DeepMind

Sonic HealthPlus | SONIC CLINICAL SERVICES

5D CLINICS

emyria

Palantir linear

Stanford University

Jazz Pharmaceuticals

antares

ACCELERON PHARMA

Oak St. Health

[redacted]

Stanford University

Bupa UCL

DeepMind

The Academy of Medical Sciences

EPIDEMIOLOGY OF PTSD and Tr-Depression in Australia [1]

	Adults aged 18-80 (millions) [1]	% with condition	Adults with condition	% with chronic and severe	Adult PTSD cases that are chronic or severe	% with disqualifying condition [3]	Adult PTSD cases eligible for MDMA-AT
PTSD	20.7	7-11% [2]	2,277,000	50% [3]	1,138,500	22% [3]	888,030
Tr-Dep	20.7	4-6% [4]	1,242,000	50% [4]	621,000	22% [3]	484,380

Sources:
1. https://www.abs.gov.au/statistics/people/population/population-clock-pyramid
2. **7%**: - https://www.phoenixaustralia.org/ptsd-awareness-day/ **11%**: https://www.aihw.gov.au/reports/mental-health/stress-and-trauma
3. https://link.springer.com/article/10.1007/s40261-022-01122-0#Fig2, disqualifying conditions can comprise certain cardiovascular risk factors or a history of psychotic disorder
4. https://www.blackdoginstitute.org.au/wp-content/uploads/2020/04/1-facts_figures.pdf